House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Cardiology

Primary PCI for acute coronary syndromes: CVIT expert consensus

Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

CVIT’s 2026 expert consensus updates procedural management of acute coronary syndromes in Japanese practice. This selected summary covers invasive timing, PCI access and devices, intracoronary imaging, shock, multivessel intervention and selected antiplatelet decisions. It preserves Japanese availability constraints and separates unstable patients from stable candidates for broader revascularisation.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Select the invasive strategy

  • For STEMI, primary PCI of the infarct-related artery is recommended. For NSTE-ACS, distinguish very high-risk instability requiring immediate intervention from the stable high-risk group considered for early angiography. [1]
  • Use an immediate invasive strategy for very high-risk NSTE-ACS: haemodynamic instability or cardiogenic shock, recurrent or refractory pain despite treatment, life-threatening arrhythmias, mechanical infarct complications, ACS-related heart failure, or recurrent dynamic ST/T changes, particularly intermittent ST elevation. [1]
  • For high-risk NSTE-ACS, consider an early invasive strategy within 24 hours. The high-risk criteria include confirmed NSTEMI under the high-sensitivity troponin algorithm, dynamic ST/T changes, transient ST elevation or GRACE above 140. The article varies in its wording of recommendation strength for this timing. [1]

Antithrombotics, access and device choice

  • During primary PCI, give procedural anticoagulation in addition to antiplatelet therapy; the consensus recommends routine unfractionated heparin. This statement is about procedural treatment and does not establish a routine prolonged post-procedure anticoagulation indication. [1]
  • Prefer radial over femoral access when the procedure is performed by an experienced radial operator. Operator expertise is an explicit condition of this recommendation. [1]
  • Consider direct stenting during primary PCI. A balloon-angioplasty-only strategy is not recommended over direct stenting; when stenting ACS lesions, prefer a recent-generation drug-eluting stent to a bare-metal stent. [1]
  • A drug-coated balloon can be considered for ACS PCI if implantation of a drug-eluting stent is not feasible. The document describes the evidence for this approach in ACS as limited. [1]
  • Treat the aspiration recommendation as specific to Japanese practice: CVIT advises considering aspiration for thrombotic STEMI or NSTE-ACS lesions where GP IIb/IIIa inhibitors are unavailable in Japan. The same document notes that routine aspiration is not recommended by ESC guidance, so this is not a universal routine-aspiration rule. [1]
  • Consider distal protection selectively for large plaque burden with a high likelihood of distal embolisation or no-reflow, or for infarction involving a saphenous vein graft. This is a selected-case option rather than routine protection for every PCI. [1]
  • Intravenous nicorandil may be considered before primary PCI in STEMI within 12 hours of symptom onset to reduce microvascular impairment. Intracoronary nicorandil can be considered as bailout for slow-flow or no-reflow; these are options, not mandatory treatment for all patients. [1]

Optimise and inspect the PCI result

  • Use IVUS or OCT to guide PCI optimisation. In non-left-main lesions, the consensus targets relative stent expansion above 80%, with minimum stent area above 5.5 mm² by IVUS or above 4.5 mm² by OCT; do not transfer these area targets to left-main lesions. [1]
  • Consider intracoronary imaging to identify stent-related mechanical problems. Post-procedure OCT or optical frequency-domain imaging assesses dissection, incomplete apposition and thrombus protrusion; the consensus treats this assessment as potentially improving long-term outcomes. [1]
  • Consider additional post-dilatation when acute malapposition exceeds 250 microns; smaller gaps may resolve. Most OCT-detected edge dissections are clinically silent, but additional stenting may be performed when distal-edge dissection width is at least 200 microns. [1]

Shock and multivessel disease

  • Do not use intra-aortic balloon pumping routinely. Consider it when haemodynamic instability or cardiogenic shock results from mechanical complications. In refractory shock, short-term Impella or ECMO support may be considered in selected institutions. [1]
  • For stable STEMI with multivessel disease, complete revascularisation is recommended during the index PCI or within 45 days. For stable NSTE-ACS with multivessel disease, the consensus recommends complete revascularisation, preferably during the index procedure. [1]
  • In cardiogenic shock, do not perform non-infarct-related artery PCI during the index procedure. Preserve this exception when considering the broader complete-revascularisation recommendation. [1]

Tailor treatment after PCI

  • After PCI in patients at high bleeding risk, consider 1 month of dual antiplatelet therapy followed by potent P2Y12-inhibitor monotherapy, irrespective of coronary complexity. The suggested agents are prasugrel or ticagrelor; the document discourages assuming the same strategy with clopidogrel after only 1 month in ACS. [1]
  • For patients without high bleeding risk who remain event-free after 3–6 months of dual antiplatelet therapy, consider single-agent therapy, preferably prasugrel or ticagrelor. To reduce bleeding, switching from prasugrel or ticagrelor to clopidogrel can be considered after 30 days from ACS. [1]
  • Use a proton-pump inhibitor alongside dual antiplatelet therapy for patients at high risk of gastrointestinal bleeding. Keep the bleeding-risk qualification when applying this gastroprotection recommendation. [1]
  • When suspected infarction has no significant obstructive coronary lesion, regard MINOCA as a working diagnosis requiring investigation. Distinguish ischaemic infarction from non-ischaemic myocardial injury rather than ending the assessment with the angiographic finding. [1]

Limitations and use

  • This is a selected procedural summary, not a complete ACS diagnostic, resuscitation, contraindication or drug-prescribing protocol. Japanese drug availability and locally reduced prasugrel dosing require separate interpretation outside Japan; loading and maintenance doses are not reproduced here.
  • The source uses both recommended and should be considered for early invasive treatment of high-risk NSTE-ACS. This summary retains the more qualified wording and does not equate stable high-risk disease with the very-high-risk immediate-intervention group.
  • Detailed atrial-fibrillation combination therapy, left-ventricular thrombus anticoagulation, vulnerable-plaque preventive stenting, physiological assessment and device-specific technical instructions are not covered. Antiplatelet options require individual bleeding and thrombotic risk assessment.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Primary PCI for acute coronary syndromes: CVIT expert consensus

    Selected recommendation material consulted

Expert consensus

Publication details

Issuing organisation
Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT)
Resource type
Expert consensus · House clinical summary

Earlier House summaries: primary pci for acute coronary syndrome esc

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Select the invasive strategy
  • Antithrombotics, access and device choice
  • Optimise and inspect the PCI result
  • Shock and multivessel disease
  • Tailor treatment after PCI
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House